A biologic switch appears to enhance response in plaque psoriasis. The effectiveness of switching to certain biologics, such as etanercept biosimilars, is being reported, although the specific details and outcomes are not entirely clear. Research on treatments for plaque psoriasis, including anti-interleukin-23 antibodies, is also being explored in various studies and registries.